Foster Victor Wealth Advisors LLC Has $19.35 Million Position in Boston Scientific Corporation $BSX

Foster Victor Wealth Advisors LLC boosted its stake in shares of Boston Scientific Corporation (NYSE:BSX) by 8.0% during the third quarter, Holdings Channel.com reports. The fund owned 198,778 shares of the medical equipment provider’s stock after acquiring an additional 14,793 shares during the period. Boston Scientific comprises 1.2% of Foster Victor Wealth Advisors LLC’s investment portfolio, making the stock its 23rd largest position. Foster Victor Wealth Advisors LLC’s holdings in Boston Scientific were worth $19,345,000 as of its most recent SEC filing.

A number of other institutional investors have also recently modified their holdings of BSX. Norges Bank bought a new position in shares of Boston Scientific in the second quarter worth $2,089,937,000. Edgewood Management LLC acquired a new stake in Boston Scientific during the second quarter worth about $746,655,000. Bessemer Group Inc. increased its holdings in Boston Scientific by 14,391.8% in the 2nd quarter. Bessemer Group Inc. now owns 2,919,801 shares of the medical equipment provider’s stock valued at $313,618,000 after buying an additional 2,899,653 shares during the period. Vanguard Group Inc. raised its position in shares of Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after buying an additional 2,545,381 shares in the last quarter. Finally, Bank of Nova Scotia lifted its holdings in shares of Boston Scientific by 106.4% during the 2nd quarter. Bank of Nova Scotia now owns 3,025,519 shares of the medical equipment provider’s stock worth $324,971,000 after acquiring an additional 1,559,605 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In related news, Director Ellen M. Zane sold 12,891 shares of the business’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total value of $1,266,927.48. Following the sale, the director owned 24,134 shares of the company’s stock, valued at $2,371,889.52. The trade was a 34.82% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was sold at an average price of $101.55, for a total value of $1,758,135.15. Following the transaction, the executive vice president directly owned 23,600 shares of the company’s stock, valued at approximately $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold 143,095 shares of company stock valued at $14,228,950 in the last ninety days. 0.50% of the stock is currently owned by insiders.

Boston Scientific Price Performance

Shares of BSX opened at $95.61 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. The stock has a market cap of $141.74 billion, a PE ratio of 51.13, a PEG ratio of 1.93 and a beta of 0.67. Boston Scientific Corporation has a 12-month low of $85.98 and a 12-month high of $109.50. The business has a 50-day simple moving average of $98.64 and a two-hundred day simple moving average of $101.26.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.71 by $0.04. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The company had revenue of $5.07 billion for the quarter, compared to analysts’ expectations of $4.97 billion. During the same period in the previous year, the business posted $0.63 earnings per share. The business’s quarterly revenue was up 20.3% compared to the same quarter last year. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. Analysts anticipate that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BSX shares. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Wall Street Zen lowered Boston Scientific from a “buy” rating to a “hold” rating in a research note on Saturday. Truist Financial lowered their price target on Boston Scientific from $130.00 to $120.00 and set a “buy” rating for the company in a report on Thursday. UBS Group reaffirmed a “buy” rating on shares of Boston Scientific in a research note on Wednesday. Finally, Needham & Company LLC reissued a “buy” rating and issued a $121.00 target price on shares of Boston Scientific in a report on Friday, October 17th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and a consensus target price of $124.85.

Trending Headlines about Boston Scientific

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: RBC Capital continues to rate BSX as an “outperform,” reinforcing buy-side support from a major bank and likely helping demand for shares. RBC Capital maintains Boston Scientific (BSX) outperform recommendation
• Positive Sentiment: Royal Bank of Canada analyst commentary suggests upside ahead for BSX, adding another institutional voice expecting price appreciation. This supports the bullish narrative among analysts. Boston Scientific (NYSE:BSX) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says
• Positive Sentiment: Truist reaffirmed a “buy” rating on BSX, signaling continued analyst confidence even as the firm updated its outlook—this helps underwrite medium-term investor sentiment. Truist Securities maintains Boston Scientific (BSX) buy recommendation
• Positive Sentiment: Zacks highlights BSX’s global expansion push — R&D, AI-driven manufacturing and a focused Emerging Markets effort targeting $1B+ revenue in China for 2025 — a strategic growth catalyst that supports longer-term upside. Boston Scientific’s Global Expansion: What’s Behind the Growth?
• Neutral Sentiment: Options flow is active around BSX; Benzinga’s options-focused piece notes positioning that can amplify intraday moves but doesn’t definitively indicate directional conviction from fundamental investors. Watch open interest and strike concentration for short-term signals. Decoding Boston Scientific’s Options Activity: What’s the Big Picture?
• Neutral Sentiment: Informational pieces recap BSX’s multi-year performance; useful for context but unlikely to move the stock today. These highlight solid historical returns that underpin investor confidence. Here’s How Much You Would Have Made Owning Boston Scientific Stock In The Last 5 Years
• Neutral Sentiment: Short-term market commentary notes BSX outperformed earlier sessions; useful for momentum traders but not a standalone fundamental driver. Boston Scientific (BSX) Advances While Market Declines
• Negative Sentiment: Truist cut its price target from $130 to $120 — a downward revision that may cap near-term upside and pressures sentiment despite the maintained “buy” rating. That target trim likely explains some of the selling pressure today. BSX price target lowered by Truist

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.